Improving the resistance profile of hepatitis C NS3/4A inhibitors: Dynamic substrate envelope guided design

Journal of Chemical Theory and Computation

Volumn 9, Issue 12, 2013, Pages 5693-5705

  Özen, Ayşegül ^a   Sherman, Woody ^b   Schiffer, Celia A ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b SCHRÖDINGER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84890495645     PISSN: 15499618     EISSN: 15499626     Source Type: Journal    
DOI: 10.1021/ct400603p     Document Type: Article

References (47)

1. Seiwert, S. D., Kossen, K., Pan, L., Liu, J., and Buckman, B. O. Discovery and Development of the HCV NS3/4A Protease Inhibitor Danoprevir (ITMN-191/RG7227). In Antiviral Drugs; John Wiley & Sons, Inc.: 2011; pp 257-271.
2. Harper, S.; McCauley, J. A.; Rudd, M. T.; Ferrara, M.; DiFilippo, M.; Crescenzi, B.; Koch, U.; Petrocchi, A.; Holloway, M. K.; Butcher, J. W.; Romano, J. J.; Bush, K. J.; Gilbert, K. F.; McIntyre, C. J.; Nguyen, K. T.; Nizi, E.; Carroll, S. S.; Ludmerer, S. W.; Burlein, C.; DiMuzio, J. M.; Graham, D. J.; McHale, C. M.; Stahlhut, M. W.; Olsen, D. B.; Monteagudo, E.; Cianetti, S.; Giuliano, C.; Pucci, V.; Trainor, N.; Fandozzi, C. M.; Rowley, M.; Coleman, P. J.; Vacca, J. P.; Summa, V.; Liverton, N. J. Discovery of MK-5172, a macrocyclic hepatitis C virus NS3/4a protease inhibitor ACS Med. Chem. Lett. 2012, 3 (4) 332-336
3. McCauley, J. A.; McIntyre, C. J.; Rudd, M. T.; Nguyen, K. T.; Romano, J. J.; Butcher, J. W.; Gilbert, K. F.; Bush, K. J.; Holloway, M. K.; Swestock, J.; Wan, B. L.; Carroll, S. S.; DiMuzio, J. M.; Graham, D. J.; Ludmerer, S. W.; Mao, S. S.; Stahlhut, M. W.; Fandozzi, C. M.; Trainor, N.; Olsen, D. B.; Vacca, J. P.; Liverton, N. J. Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitor J. Med. Chem. 2010, 53 (6) 2443-2463
4. Qureshi, S. A. Hepatitis C virus - Biology, host evasion strategies, and promising new therapies on the horizon Med. Res. Rev. 2007, 27 (3) 353-373
5. Cabot, B.; Martell, M.; Esteban, J. I.; Piron, M.; Otero, T.; Esteban, R.; Guardia, J.; Gomez, J. Longitudinal evaluation of the structure of replicating and circulating hepatitis C virus quasispecies in nonprogressive chronic hepatitis C patients J. Virol. 2001, 75 (24) 12005-12013
6. Martell, M.; Esteban, J. I.; Quer, J.; Genesca, J.; Weiner, A.; Esteban, R.; Guardia, J.; Gomez, J. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: Quasispecies nature of HCV genome distribution J. Virol. 1992, 66 (5) 3225-3229
7. Chellappan, S.; Kiran Kumar Reddy, G. S.; Ali, A.; Nalam, M. N.; Anjum, S. G.; Cao, H.; Kairys, V.; Fernandes, M. X.; Altman, M. D.; Tidor, B.; Rana, T. M.; Schiffer, C. A.; Gilson, M. K. Design of mutation-resistant HIV protease inhibitors with the substrate envelope hypothesis Chem. Biol. Drug Des. 2007, 69 (5) 298-313
8. Altman, M. D.; Ali, A.; Reddy, G. S.; Nalam, M. N.; Anjum, S. G.; Cao, H.; Chellappan, S.; Kairys, V.; Fernandes, M. X.; Gilson, M. K.; Schiffer, C. A.; Rana, T. M.; Tidor, B. HIV-1 protease inhibitors from inverse design in the substrate envelope exhibit subnanomolar binding to drug-resistant variants J. Am. Chem. Soc. 2008, 130 (19) 6099-6113
9. Kairys, V.; Gilson, M. K.; Lather, V.; Schiffer, C. A.; Fernandes, M. X. Toward the design of mutation-resistant enzyme inhibitors: further evaluation of the substrate envelope hypothesis Chem. Biol. Drug Des. 2009, 74 (3) 234-245
10. Altman, M. D.; Nalivaika, E. A.; Prabu-Jeyabalan, M.; Schiffer, C. A.; Tidor, B. Computational design and experimental study of tighter binding peptides to an inactivated mutant of HIV-1 protease Proteins 2008, 70 (3) 678-694
11. Nalam, M. N.; Ali, A.; Altman, M. D.; Reddy, G. S.; Chellappan, S.; Kairys, V.; Ozen, A.; Cao, H.; Gilson, M. K.; Tidor, B.; Rana, T. M.; Schiffer, C. A. Evaluating the substrate-envelope hypothesis: Structural analysis of novel HIV-1 protease inhibitors designed to be robust against drug resistance J. Virol. 2010, 84 (10) 5368-5378
12. Prabu-Jeyabalan, M.; Nalivaika, E.; Schiffer, C. A. Substrate shape determines specificity of recognition for HIV-1 protease: Analysis of crystal structures of six substrate complexes Structure 2002, 10 (3) 369-381
13. Ozen, A.; Haliloglu, T.; Schiffer, C. A. Dynamics of preferential substrate recognition in HIV-1 protease: Redefining the substrate envelope J. Mol. Biol. 2011, 410 (4) 726-744
14. Ozen, A.; Haliloglu, T.; Schiffer, C. A. HIV-1 protease and substrate coevolution validates the substrate envelope as the recognition pattern J. Chem. Theory Comput. 2012, 8, 703-714
15. King, N. M.; Prabu-Jeyabalan, M.; Nalivaika, E. A.; Schiffer, C. A. Combating susceptibility to drug resistance: lessons from HIV-1 protease Chem. Biol. 2004, 11 (10) 1333-1338
16. Kim, J. L.; Morgenstern, K. A.; Griffith, J. P.; Dwyer, M. D.; Thomson, J. A.; Murcko, M. A.; Lin, C.; Caron, P. R. Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: The crystal structure provides insights into the mode of unwinding Structure 1998, 6 (1) 89-100
17. Yao, N.; Hesson, T.; Cable, M.; Hong, Z.; Kwong, A. D.; Le, H. V.; Weber, P. C. Structure of the hepatitis C virus RNA helicase domain Nat. Struct. Biol. 1997, 4 (6) 463-467
18. Romano, K. P.; Ali, A.; Royer, W. E.; Schiffer, C. A. Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding Proc. Natl. Acad. Sci. U.S.A. 2010, 107 (49) 20986-20991
19. Yao, N.; Reichert, P.; Taremi, S. S.; Prosise, W. W.; Weber, P. C. Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase Structure 1999, 7 (11) 1353-1363
20. Romano, K. P.; Ali, A.; Aydin, C.; Soumana, D.; Ozen, A.; Deveau, L. M.; Silver, C.; Cao, H.; Newton, A.; Petropoulos, C. J.; Huang, W.; Schiffer, C. A. The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors PLoS Pathog. 2012, 8 (7) e1002832
21. Ali, A.; Aydin, C.; Gildemeister, R.; Romano, K. P.; Cao, H.; Ozen, A.; Soumana, D.; Newton, A.; Petropoulos, C. J.; Huang, W.; Schiffer, C. A. Evaluating the role of macrocycles in the susceptibility of hepatitis C virus NS3/4A protease inhibitors to drug resistance ACS Chem. Biol. 2013, 8 (7) 1469-1478
22. Lin, C.; Thomson, J. A.; Rice, C. M. A central region in the hepatitis C virus NS4A protein allows formation of an active NS3-NS4A serine proteinase complex in vivo and in vitro J. Virol. 1995, 69 (7) 4373-4380
23. Bartenschlager, R.; Ahlborn-Laake, L.; Mous, J.; Jacobsen, H. Kinetic and structural analyses of hepatitis C virus polyprotein processing J. Virol. 1994, 68 (8) 5045-5055
24. Lin, C.; Pragai, B. M.; Grakoui, A.; Xu, J.; Rice, C. M. Hepatitis C virus NS3 serine proteinase: Trans-cleavage requirements and processing kinetics J. Virol. 1994, 68 (12) 8147-8157
25. Xue, W.; Ban, Y.; Liu, H.; Yao, X. Computational study on the drug resistance mechanism against HCV NS3/4A protease inhibitors vaniprevir and MK-5172 by the combination use of molecular dynamics simulation, residue interaction network, and substrate envelope analysis J. Chem. Inf. Model. 2013, 10.1021/ci400060j
26. Shiryaev, S. A.; Thomsen, E. R.; Cieplak, P.; Chudin, E.; Cheltsov, A. V.; Chee, M. S.; Kozlov, I. A.; Strongin, A. Y. New details of HCV NS3/4A proteinase functionality revealed by a high-throughput cleavage assay PLoS One 2012, 7 (4) e35759
27. Cummings, M. D.; Lindberg, J.; Lin, T. I.; de Kock, H.; Lenz, O.; Lilja, E.; Fellander, S.; Baraznenok, V.; Nystrom, S.; Nilsson, M.; Vrang, L.; Edlund, M.; Rosenquist, A.; Samuelsson, B.; Raboisson, P.; Simmen, K. Induced-fit binding of the macrocyclic noncovalent inhibitor TMC435 to its HCV NS3/NS4A protease target Angew. Chem., Int. Ed. 2010, 49 (9) 1652-1655
28. Velazquez-Campoy, A.; Freire, E. Incorporating target heterogeneity in drug design J. Cell. Biochem. Suppl. 2001, Suppl 37, 82-88
29. Summa, V.; Ludmerer, S. W.; McCauley, J. A.; Fandozzi, C.; Burlein, C.; Claudio, G.; Coleman, P. J.; Dimuzio, J. M.; Ferrara, M.; Di Filippo, M.; Gates, A. T.; Graham, D. J.; Harper, S.; Hazuda, D. J.; McHale, C.; Monteagudo, E.; Pucci, V.; Rowley, M.; Rudd, M. T.; Soriano, A.; Stahlhut, M. W.; Vacca, J. P.; Olsen, D. B.; Liverton, N. J.; Carroll, S. S. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants Antimicrob. Agents Chemother. 2012, 56 (8) 4161-4167
30. Romano, K. P.; Laine, J. M.; Deveau, L. M.; Cao, H.; Massi, F.; Schiffer, C. A. Molecular mechanisms of viral and host cell substrate recognition by hepatitis C virus NS3/4A protease J. Virol. 2011, 85 (13) 6106-6116
31. Snyder, P. W.; Mecinovic, J.; Moustakas, D. T.; Thomas, S. W., 3rd; Harder, M.; Mack, E. T.; Lockett, M. R.; Heroux, A.; Sherman, W.; Whitesides, G. M. Mechanism of the hydrophobic effect in the biomolecular recognition of arylsulfonamides by carbonic anhydrase Proc. Natl. Acad. Sci. U.S.A. 2011, 108 (44) 17889-17894
32. Beuming, T.; Che, Y.; Abel, R.; Kim, B.; Shanmugasundaram, V.; Sherman, W. Thermodynamic analysis of water molecules at the surface of proteins and applications to binding site prediction and characterization Proteins 2012, 80 (3) 871-883
33. Robinson, D. D.; Sherman, W.; Farid, R. Understanding kinase selectivity through energetic analysis of binding site waters ChemMedChem 2010, 5 (4) 618-627
34. Huggins, D. J.; Sherman, W.; Tidor, B. Rational approaches to improving selectivity in drug design J. Med. Chem. 2012, 55 (4) 1424-1444
35. Suite 2011: Prime, version 3.0; Schrödinger, LLC: New York, 2011.
36. Davis, A. M.; Teague, S. J.; Kleywegt, G. J. Application and limitations of X-ray crystallographic data in structure-based ligand and drug design Angew. Chem., Int. Ed. 2003, 42 (24) 2718-2736
37. Madhavi Sastry, G.; Adzhigirey, M.; Day, T.; Annabhimoju, R.; Sherman, W. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments J. Comput.-Aided Mol. Des. 2013, 27 (3) 221-234
38. Suite 2011: Maestro, version 9.2; Schrödinger, LLC: Portland, OR, 2011.
39. Bowers, K. J.; Chow, E.; Xu, H.; Dror, R. O.; Eastwood, M. P.; Gregersen, B. A.; Klepeis, J. L.; Kolossvary, I.; Moraes, M. A.; Sacerdoti, F. D.; Salmon, J. K.; Shan, Y.; Shaw, D. E. Scalable Algorithms for Molecular Dynamics Simulations on Commodity Clusters. Proceedings of the ACM/IEEE Conference on Supercomputing (SC06), Tampa, Florida 2006.
40. Suite 2011: Desmond Molecular Dynamics System, version 3.0; D. E. Shaw Research: New York, 2011. Maestro-Desmond Interoperability Tools, version 3.0; Schrödinger: New York, 2011.
41. Jorgensen, W. L.; Chandrasekhar, J.; Madura, J. D.; Impey, R. W.; Klein, M. L. Comparison of simple potential functions for simulating liquid water J. Chem. Phys. 1983, 79, 926-935
42. Shivakumar, D.; Williams, J.; Wu, Y.; Damm, W.; Shelley, J.; Sherman, W. Prediction of absolute solvation free energies using molecular dynamics free energy perturbation and the OPLS force field J. Chem. Theory Comput. 2010, 6, 1509-1519
43. Darden, T.; Darrin, Y.; Pedersen, L. Particle mesh Ewald: An NâŠlog(N) method for Ewald sums in large systems J. Chem. Phys. 1993, 98, 10089-10093
44. Essmann, U.; Perera, L.; Berkowitz, M. L.; Darden, T.; Lee, H.; Pedersen, L. G. A smooth particle mesh ewald method J. Chem. Phys. 1995, 103 (19) 8577-8593
45. Humphrey, W.; Dalke, A.; Schulten, K. VMD: Visual molecular dynamics J. Mol. Graph. 1996, 14 (1) 33-38
46. 27-38.
47. The PyMOL Molecular Graphics System; Schrödinger, LLC: New York, 2011.